San Diego-based mostly Viking Therapeutics marked itself as a serious competitor while in the weight loss drug market place in February soon after revealing promising details from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented like a weekly injection and in March the